Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2008

View Archived Issues

Recent patents cover new agents for endocrine disorders

Novel agents with possible use in obesity and other metabolic disorders described in recent patents

Radiosensitization seen with CEP-9722 in radioresistant glioblastoma xenografts

Eg5 kinesin inhibitor with cytotoxic activity discovered at ArQule

Destiny Pharma's XF-73 demonstrates activity against Gram-positive bacteria

Compugen discovers blood-based biomarker for diagnosis of lung cancer

DOR BioPharma initiates nonhuman primate efficacy studies of RiVax ricin toxin vaccine

Genentech and Biogen report negative results from phase II/III study of Rituxan in SLE

Insmed presents development update on Iplex and the follow-on biologics INS-19 and INS-20

Antisoma presents update on clinical development activities of its anticancer compounds

Alexza reports positive results from phase I clinical trial of Staccato for insomnia

Recent Pfizer and AstraZeneca patents disclose new treatment options for respiratory disorders

Safe delivery of gene therapy for the treatment of retinal dystrophy

Resolvin E1 analogues improve dry eye symptoms and may be suitable for other ocular disorders

AstraZeneca submits sNDA for Symbicort for COPD

MediQuest submits NDA to FDA to treat Raynaud's disease

SkyePharma presents positive phase III efficacy data for Flutiform

Regression of CNV with novel pan-tubulin inhibitor OC-10X

Merck Serono and ZymoGenetics initiate phase II clinical trial of atacicept in RMS

Partial efficacy of Merck & Co.'s novel SSTR2 antagonists in models of CNV

Lundbeck obtains expanded rights from Neurim to commercialize Circadin outside of E.U.

ISTA Pharmaceuticals presents new phase III clinical findings to support Bepreve NDA

FDA approves Advair 250/50 for reduction of exacerbations in COPD patients

Innocoll initiates dosing in phase II clinical trial of CollaRx gentamicin topical sponge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...